Annals of Oncology最新文献

{"title":"Cytokine release symptoms rather than syndromes: a call for granular reporting of cytokine-related adverse events in clinical trials","authors":"J.-D. Fumet,&nbsp;M.R. Dugage,&nbsp;F.-X. Danlos,&nbsp;T. Hueso,&nbsp;D.J. Pinato,&nbsp;J. Luke,&nbsp;I.M. Bermejo,&nbsp;P. Lorusso,&nbsp;J. Brody,&nbsp;K. Harrington,&nbsp;N.H. Segal,&nbsp;A. Diab,&nbsp;E. Garralda,&nbsp;T. Marron,&nbsp;R. Houot,&nbsp;S. Champiat,&nbsp;A. Marabelle","doi":"10.1016/j.annonc.2026.03.006","DOIUrl":"10.1016/j.annonc.2026.03.006","url":null,"abstract":"<div><h3>Background</h3><div>T-cell redirecting therapies, notably chimeric antigen receptor T cells and bispecific antibodies, have revolutionized the treatment of hematologic malignancies. Their rapid expansion into solid tumors, alongside the emergence of next-generation agents, such as immunocytokines and CD28-costimulatory bispecifics, has brought cytokine release syndrome (CRS) to the forefront of clinical oncology. However, the absence of a unified grading system for these novel constructs remains a critical barrier to drug development and patient safety.</div><div>Current toxicity management relies on disparate grading scales, leading to inconsistent reporting and hindering cross-trial comparisons. A fundamental challenge lies in the diagnostic ambiguity created by the significant clinical and temporal overlap among CRS, infusion-related reactions, and other diagnoses. Although fever, hypotension, and hypoxia are common denominators, their distinct pathophysiological drivers necessitate divergent therapeutic interventions.</div></div><div><h3>Design</h3><div>We advocate for a paradigm shift from aggregate syndromic grading toward a granular, longitudinal reporting framework. This approach prioritizes the precise documentation of symptom kinetics, specific interventions (e.g. exact vasopressor requirements and oxygen flow rates), and real-time biomarker integration. By capturing high-fidelity data, researchers can retrospectively apply evolving criteria and develop more tailored, evidence-based management algorithms.</div></div><div><h3>Conclusion</h3><div>Transitioning to a standardized, symptom-driven reporting model is essential to navigate the complexities of ‘Immuno-oncology 2.0.’ Such a framework will harmonize safety assessments across global trials and ultimately optimize the therapeutic index of next-generation immunotherapies.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 7","pages":"Pages 892-901"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147615745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2− and ADAPTcycle trials (N = 7914)","authors":"O. Gluz,&nbsp;U. Nitz,&nbsp;M. Christgen,&nbsp;S. Kuemmel,&nbsp;M. Braun,&nbsp;M. Thill,&nbsp;R. Wuerstlein,&nbsp;T. Link,&nbsp;B. Aktas,&nbsp;K. Lüdtke-Heckenkamp,&nbsp;M. Zaiss,&nbsp;V. Bjelic-Radisic,&nbsp;M. Just,&nbsp;K. Veselinovic,&nbsp;M. Vincent,&nbsp;R. Baehner,&nbsp;L. Wujak,&nbsp;M. Warm,&nbsp;C. Schumacher,&nbsp;C. Schem,&nbsp;N. Harbeck","doi":"10.1016/j.annonc.2026.04.007","DOIUrl":"10.1016/j.annonc.2026.04.007","url":null,"abstract":"<div><h3>Background</h3><div>Low Ki67 after short preoperative endocrine therapy (ET) indicates a favorable prognosis in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC). We investigated predictors of ET response in the West German Study Group (WSG) ADAPT-HR+/HER2− and ADAPTcycle trials.</div></div><div><h3>Patients and methods</h3><div>ET response (Ki67 ≤10%) after 2- to 4-week standard ET, recurrence score (RS), and nodal status were used for treatment allocation. In ADAPT-HR+/HER2−, patients at high clinical risk received ET alone if N0-1 and RS 0-11 or RS 12-25 and ET response. In ADAPTcycle, N0-1 patients with RS &gt; 25 and ET response and those with RS &lt; 25 and e.g. ET nonresponse, N2-3 patients with RS ≤ 25 and ET response, were randomly assigned to receive (neo)adjuvant chemotherapy or aromatase inhibitor (AI)+ribociclib. Predictors of ET response were identified through multivariable logistic regression models.</div></div><div><h3>Results</h3><div>Three thousand six hundred seventy-five patients from the ADAPT-HR+/HER2− cohort (≤50 years and premenopausal, ≤50 years: <em>N</em> = 1250; &gt;50 years or postmenopausal, &gt;50 years: <em>N</em> = 2425) and 4239 from the ADAPTcycle screening cohort (≤50 years: <em>N</em> = 1336; &gt;50 years: <em>N</em> = 2903) were analyzed. ET response rates were higher after AI (ADAPT-HR+/HER2−/ADAPTcycle: 81.4%/76.7%) versus tamoxifen (ADAPT-HR+/HER2−/ADAPTcycle: 40.1%/34.7%) in both age groups, with further improvement by ovarian function suppression (OFS) in premenopausal patients. Premenopausal patients with GnRH plus AI had similar ET response rates as postmenopausal patients. ET response predictors included AI use (plus OFS in premenopausal), age &gt;50 years, lower RS and baseline Ki67 levels, and higher expression of estrogen receptor (by immunohistochemistry) and HER2 (by Oncotype DX™).</div><div>In ADAPT-HR+/HER2−, 5-year distant disease-free survival in ET responders was markedly higher than in nonresponders and also in chemotherapy-treated N0-1 patients with RS &gt; 25 (87.0 versus 80.7%), and it was only slightly lower than that in the RS 12-25 group.</div></div><div><h3>Conclusions</h3><div>We observed similar ET response rates in two large phase III trials. Postmenopausal patients (mostly receiving AI) had higher ET response rates than younger patients. However, young patients with GnRH+AI had ET response rates comparable with those of postmenopausal patients, suggesting that therapy rather than biology accounts for the difference. Combining ET response and gene expression assessment could help more patients with luminal eBC avoid chemotherapy.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 7","pages":"Pages 920-935"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147715680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic","authors":"K.V. Giridhar,&nbsp;M.P. Goetz","doi":"10.1016/j.annonc.2026.05.702","DOIUrl":"10.1016/j.annonc.2026.05.702","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 7","pages":"Pages 873-876"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148315139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"106P Immune and metabolic profiles of colorectal (CRC) metastases are associated with avelumab benefit in patients with MSS chemorefractory mCRC","authors":"E. Benidovskaya,&nbsp;N. Huyghe,&nbsp;J. Carrasco,&nbsp;A. De Cuyper,&nbsp;I. Sinapi,&nbsp;M-L. Castella,&nbsp;H. Dahou,&nbsp;C. Bouzin,&nbsp;J. Galon,&nbsp;W.R.L. Hendrickx,&nbsp;P.G. Coulie,&nbsp;M. van den Eynde","doi":"10.1016/j.annonc.2026.05.107","DOIUrl":"10.1016/j.annonc.2026.05.107","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S41"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148529608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"52P Optimizing therapeutic sequencing in patients aged ≥80 years with refractory metastatic colorectal cancer: Real-world evidence from the ReTrITA study","authors":"C. Signorelli,&nbsp;A. Passardi,&nbsp;M. Basso,&nbsp;C. Gallio,&nbsp;A. Anghelone,&nbsp;M.A. Calegari,&nbsp;L. Angotti,&nbsp;I.V. Zurlo,&nbsp;E. Dell'Aquila,&nbsp;D. Gemma,&nbsp;M. Ribelli,&nbsp;G. Arrivi,&nbsp;F. Zoratto,&nbsp;M.G. Morandi,&nbsp;F. Santamaria,&nbsp;A. Cosimati,&nbsp;R. Saltarelli,&nbsp;A. Minelli,&nbsp;E. Lucci-Cordisco,&nbsp;D.C. Corsi","doi":"10.1016/j.annonc.2026.05.054","DOIUrl":"10.1016/j.annonc.2026.05.054","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S21"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148529696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"74P Machine learning-derived serum biomarker signatures for treatment selection and monitoring in advanced colorectal cancer patients receiving trifluridine/tipiracil plus ramucirumab: Translational analysis of the RAMTAS trial (AIO-KRK-0316/IKF643)","authors":"A. Lahusen,&nbsp;L. Perkhofer,&nbsp;J. Schuhbaur,&nbsp;A. Kestler,&nbsp;S. Stintzing,&nbsp;T. Dechow,&nbsp;M. Sinn,&nbsp;C. Roderburg,&nbsp;L. Fischer von Weikersthal,&nbsp;U. Graeven,&nbsp;A. Stein,&nbsp;D.P. Modest,&nbsp;J. Siveke,&nbsp;C. Pauligk,&nbsp;S-E. Al-Batran,&nbsp;T.O. Goetze,&nbsp;T.J. Ettrich,&nbsp;S. Kasper-Virchow,&nbsp;T. Eiseler,&nbsp;T. Seufferlein","doi":"10.1016/j.annonc.2026.05.075","DOIUrl":"10.1016/j.annonc.2026.05.075","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S28"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"89P Shifting encorafenib to first-line (1L) therapy for BRAF V600E-mutant (BRAFm) mCRC in Canada: An assessment of added benefit and cost","authors":"M.C. Vieira,&nbsp;A. Slack,&nbsp;M. El-Helou,&nbsp;H.A. Pham,&nbsp;Y. Hu","doi":"10.1016/j.annonc.2026.05.090","DOIUrl":"10.1016/j.annonc.2026.05.090","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S33"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"88P Quality of life outcomes with first-line (1L) encorafenib plus cetuximab and mFOLFOX6 (EC+mFOLFOX6) versus standard chemotherapy +/- bevacizumab in BRAF-mutant (BRAFm) V600E metastatic colorectal cancer (mCRC)","authors":"S. Lonardi,&nbsp;M.C. Vieira,&nbsp;J. Ma,&nbsp;A. Slack,&nbsp;A. Jewett,&nbsp;L. Takiya,&nbsp;B. Foster","doi":"10.1016/j.annonc.2026.05.089","DOIUrl":"10.1016/j.annonc.2026.05.089","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S33"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"68P Clinical and molecular characterization of the PKS genomic island in colorectal cancer patients from Kazakhstan","authors":"B. Kurentay,&nbsp;G. Kulmambetova,&nbsp;A. Gusmaulemova,&nbsp;A. Surdeanu","doi":"10.1016/j.annonc.2026.05.069","DOIUrl":"10.1016/j.annonc.2026.05.069","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S26"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"30P Trifluridine/tipiracil plus bevacizumab in bevacizumab naïve metastatic colorectal cancer: Real-world data from a UK population","authors":"H.L. Robbins,&nbsp;J. Iftikhar,&nbsp;K. Rakhimova,&nbsp;O.J. Pickles,&nbsp;V. Kunene,&nbsp;S. Baijal,&nbsp;B. Allos,&nbsp;J. Good,&nbsp;A.D. Beggs,&nbsp;G. Middleton,&nbsp;M.R. Openshaw","doi":"10.1016/j.annonc.2026.05.033","DOIUrl":"10.1016/j.annonc.2026.05.033","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S13"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148546325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}